| Literature DB >> 32027052 |
Selena Milicevic Sephton1, Tunde Miklovicz1,2, Joseph J Russell1, Aniruddha Doke1, Lei Li1, Istvan Boros1, Franklin I Aigbirhio1.
Abstract
An automated radiosynthesis of carbon-11 positron emission tomography radiotracer [11 C]UCB-J for imaging the synaptic density biomarker synaptic vesicle glycoprotein SV2A was established using Synthra RNPlus synthesizer. Commercially available trifluoroborate UCB-J analogue was used as a radiolabelling precursor, and the desired radiolabelled product was isolated in 11 ± 2% (n = 7) nondecay corrected radiochemical yield and formulated as a 10% EtOH solution in saline with molar activities of 20 to 100 GBq/μmol. The method was based upon the palladium(0)-mediated Suzuki cross-coupling reaction and [11 C]CH3 I as a radiolabelling synthon. The isolated product was cGMP compliant as demonstrated by the results of quality control analysis.Entities:
Keywords: SV2A protein; Suzuki cross-coupling; Synthra RNPlus; [11C]UCB-J; carbon-11 radiosynthesis; synaptic density
Year: 2020 PMID: 32027052 PMCID: PMC7155065 DOI: 10.1002/jlcr.3828
Source DB: PubMed Journal: J Labelled Comp Radiopharm ISSN: 0362-4803 Impact factor: 1.921
Figure 1Positron emission tomography radiotracers for imaging SV2A, a biomarker of synaptic density and the radiosynthetic strategy used for preparation of [11C]UCB‐J
Figure 2Automated radiosynthesizer Synthra RNPlus as the platform for the radiosynthesis of [11C]UCB‐J
Critical parameters in the radiosynthesis of [11C]UCB‐J as determined through repeated experiments (n = 54)
|
| ||
|---|---|---|
| Entry | Parameter/Step | Improvements in Reproducibility Achieved When |
| 1 | Drying activated precursor | Drying performed with vacuum in the stream of He |
| 2 | Reaction solvent DMF | Dried over molecular sieves. Bottle replaced every 2 weeks |
| 3 | Trapping of [11C]CH3I | Reaction volume in reactor 2 increased to 1.1 mL and reactor 2 pressurised before trapping |
| 4 | Semi‐prep HPLC purification | Using 5 mL injection loop and diluting the reaction mixture with eluent and filtering prior to injection |
| 5 | Quality of [11C]CH3I | Using [11C]CH3I with high molar activity |
Scheme 1Radiosyntheses of [11C]UCB‐J via direct Suzuki cross‐coupling of borate precursor 3 or via the boronic acid intermediate
Various conditions for the in situ preparation of boronic acid precursor 4
|
| ||||
|---|---|---|---|---|
| Entry | Conditions | Concentration, mg 3 in HCl: MeOH | Time, min | LCMS Conversion, % |
| 1 | HCl in dioxane | 2 mg in 0.25:2 mL | 40 | 0 |
| 2 | HCl in MeOH | 3 mg in 0.5:3 mL | 40 | 24 |
| 3 | HCl in H2O | 1.9 mg in 0.5:2 mL | 190 | 39 |
|
|
|
|
|
|
| 5 | HCl in H2O | 1.8 mg in 0.2:0.5 mL | 37 | 38 |
Aq. HCl added in 2×0.25 mL portions.
Reaction performed with the crude material.
Scheme 2Proposed mechanism of Pd‐mediated Suzuki cross‐coupling reaction to obtain [11C]UCB‐J
Figure 3Ultraviolet and radio traces for the optimized radiosynthesis of [11C]UCB‐J on Synthra RNPlus module. Note that for clarity, Ultraviolet (UV) trace is increased by threefold magnitude
Summary of the specifications used for the cGMP radiosynthesis of [11C]UCB‐J for multi dose vials
| QC Test (Parameter/Method) | Release Criteria | Production 1 | Production 2 | Production 3 |
|---|---|---|---|---|
| Appearance | Clear colourless solution | Confronts | Confronts | Confronts |
| pH | 4.5‐8.5 | 6.4 | 6.1 | 6.1 |
| HPLC system suitability test | Retention time difference less than 8 s in two injections of reference solution | pass | pass | pass |
| Radiochemical identity | Retention time of [11C]UCB‐J corresponds to that of reference UCB‐J standard, corrected for the dead‐volume between UV and radio‐detector | pass | pass | pass |
| Chemical amount of UCB‐J | ≤10 μg/dose | 8.8 | 8.6 | 6.8 |
| Chemical amount of desmethyl UCB‐J | ≤1.5 μg/dose | 0.97 | 0.59 | 0.6 |
| Chemical amount of unidentified impurity | ≤1.5 μg/dose | 1.44 | 1.38 | 1.00 |
| Total unidentified impurity | ≤3.0 μg/dose | 2.40 | 2.29 | 2.00 |
| Radiochemical purity of [11C]UCB‐J | ≥95% | 100 | 100 | 100 |
| Molar activity (GBq/μmol) | N/A | 33.0 | 23.4 | 32.1 |
| Strength (MBq in 0.1 mL) | N/A | 9.1 | 6.3 | 6.8 |
| Bacetiral endotoxins (postrelease test) | ≤175 EU/dose (≤17.5 EU/mL) | ≤2.5 EU/mL | ≤2.5 EU/mL | ≤2.5 EU/mL |
| Filter integrity (postrelease test) | Bubble point ≥46 psi (3.17 bar) | 3.8 bar | 3.7 bar | 3.8 bar |
| Sterility (postrelease test) | Pass test | pass | pass | pass |
| Residual solvent DMF (postrelease test) | ≤0.88 μg/day (≤880 ppm) | ND | ND | 1.5 |
| Formulation solvent EtOH (postrelease test) | ≤10% | 7.7% | 9.8% | 10% |
Note. The limits are per injected dose. The desmethyl UCB‐J competes with UCB‐J for the binding site for which reason the specification for desmethyl UCB‐J is stringent. The unidentified impurities include all impurities in the final formulated product, and they were calculated using 258 nm wavelength absorbance response.